Second-generation ALK inhibitors have been developed as effective drugs for ALK-positive NSCLC patients who have acquired resistance, such as alectinib, which has shown remarkable efficacy after acquired resistance to crizotinib in clinical trials [14]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.